COVID-19 and Sarcoidosis, Readiness for Vaccination: Challenges and Opportunities

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2021 May 17

PMID 33996868

Citations 13

Authors

Michael Manansala

Amit Chopra

Robert P Baughman

Richard Novak

Elyse E Lower

Daniel A Culver

Peter Korsten

Wonder P Drake

Marc A Judson

Nadera Sweiss

Affiliations

Soon will be listed here.

Abstract

Sarcoidosis is an immune mediated chronic inflammatory disorder that is best characterized by non-caseating granulomas found in one or more affected organs. The COVID-19 pandemic poses a challenge for clinicians caring for sarcoidosis patients who may be at increased risk of infection compared to the general population. With the recent availability of COVID-19 vaccines, it is expected that clinicians raise questions regarding efficacy and safety in sarcoidosis. However, studies examining safety and efficacy of vaccines in sarcoidosis are lacking. In this review, we examine the current literature regarding vaccination in immunocompromised populations and apply them to sarcoidosis patients. The available literature suggests that vaccines are safe and effective in patients with autoimmune disorders and in those taking immunosuppressive medications. We strongly recommend the administration of COVID-19 vaccines in patients with sarcoidosis. We also present a clinical decision algorithm to provide guidance on vaccination of sarcoidosis patients against COVID-19.

Citing Articles

Sarcoidal Tattoo Granuloma After COVID-19 Vaccine.

Haller C, Schnebelen A, Cadmus S JAAD Case Rep. 2024; .

PMID: 38620113 PMC: 10300053. DOI: 10.1016/j.jdcr.2023.06.022.

Infectious Complications of Pulmonary Sarcoidosis.

Valeyre D, Bernaudin J, Brauner M, Nunes H, Jeny F J Clin Med. 2024; 13(2).

PMID: 38256476 PMC: 10816300. DOI: 10.3390/jcm13020342.

Impact of different classes of immune-modulating treatments on B cell-related and T cell-related immune response before and after COVID-19 booster vaccination in patients with immune-mediated diseases and primary immunodeficiency: a cohort study.

Koehm M, Klippstein M, Dauth S, Hallmann K, Kohmer N, Burkhardt H RMD Open. 2023; 9(3).

PMID: 37652553 PMC: 10476126. DOI: 10.1136/rmdopen-2023-003094.

Initial behaviors and attitudes towards the COVID-19 vaccine in sarcoidosis patients: results of a self-reporting questionnaire.

Vagts C, Sweis J, Sweis N, Ascoli C, Rottoli P, Martone F Sarcoidosis Vasc Diffuse Lung Dis. 2023; 40(2):e2023012.

PMID: 37382069 PMC: 10494750. DOI: 10.36141/svdld.v40i2.14388.

New-onset lung sarcoidosis, an adverse event by COVID-19 or a sign of convalescence; a case report.

Sadeghi S, Reisizadeh Mobarakeh S, Momenzadeh M, Aria A, Heidarpour M, Ahmadi S Clin Case Rep. 2023; 11(5):e7339.

PMID: 37180324 PMC: 10172450. DOI: 10.1002/ccr3.7339.

References

Garg S, Kim L, Whitaker M, OHalloran A, Cummings C, Holstein R . Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(15):458-464. PMC: 7755063. DOI: 10.15585/mmwr.mm6915e3. View

van Assen S, Holvast A, Benne C, Posthumus M, Van Leeuwen M, Voskuyl A . Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2009; 62(1):75-81. DOI: 10.1002/art.25033. View

Spagnolo P, Rossi G, Trisolini R, Sverzellati N, Baughman R, Wells A . Pulmonary sarcoidosis. Lancet Respir Med. 2018; 6(5):389-402. DOI: 10.1016/S2213-2600(18)30064-X. View

Ghinai I, McPherson T, Hunter J, Kirking H, Christiansen D, Joshi K . First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. Lancet. 2020; 395(10230):1137-1144. PMC: 7158585. DOI: 10.1016/S0140-6736(20)30607-3. View

Rondaan C, Furer V, Heijstek M, Agmon-Levin N, Bijl M, Breedveld F . Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. RMD Open. 2019; 5(2):e001035. PMC: 6744079. DOI: 10.1136/rmdopen-2019-001035. View

Calender A, Israel-Biet D, Valeyre D, Pacheco Y . Modeling Potential Autophagy Pathways in COVID-19 and Sarcoidosis. Trends Immunol. 2020; 41(10):856-859. PMC: 7416769. DOI: 10.1016/j.it.2020.08.001. View

Fung T, Liu D . Human Coronavirus: Host-Pathogen Interaction. Annu Rev Microbiol. 2019; 73:529-557. DOI: 10.1146/annurev-micro-020518-115759. View

Tian S, Hu W, Niu L, Liu H, Xu H, Xiao S . Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. J Thorac Oncol. 2020; 15(5):700-704. PMC: 7128866. DOI: 10.1016/j.jtho.2020.02.010. View

Morgenthau A, Levin M, Freeman R, Reich D, Klang E . Moderate or Severe Impairment in Pulmonary Function is Associated with Mortality in Sarcoidosis Patients Infected with SARS‑CoV‑2. Lung. 2020; 198(5):771-775. PMC: 7484928. DOI: 10.1007/s00408-020-00392-9. View

10.

Haynes B, Corey L, Fernandes P, B Gilbert P, Hotez P, Rao S . Prospects for a safe COVID-19 vaccine. Sci Transl Med. 2020; 12(568). DOI: 10.1126/scitranslmed.abe0948. View

11.

Furer V, Rondaan C, Heijstek M, Agmon-Levin N, van Assen S, Bijl M . 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2019; 79(1):39-52. DOI: 10.1136/annrheumdis-2019-215882. View

12.

Wiersinga W, Rhodes A, Cheng A, Peacock S, Prescott H . Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 324(8):782-793. DOI: 10.1001/jama.2020.12839. View

13.

Curtis J, Johnson S, Anthony D, Arasaratnam R, Baden L, Bass A . American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1. Arthritis Rheumatol. 2021; 73(7):1093-1107. PMC: 8250724. DOI: 10.1002/art.41734. View

14.

Linke M, Pham H, Katholnig K, Schnoller T, Miller A, Demel F . Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. Nat Immunol. 2017; 18(3):293-302. PMC: 5321578. DOI: 10.1038/ni.3655. View

15.

Calender A, Lim C, Weichhart T, Buisson A, Besnard V, Rollat-Farnier P . Exome sequencing and pathogenicity-network analysis of five French families implicate mTOR signalling and autophagy in familial sarcoidosis. Eur Respir J. 2019; 54(2). DOI: 10.1183/13993003.00430-2019. View

16.

Kaur S, Gupta V . COVID-19 Vaccine: A comprehensive status report. Virus Res. 2020; 288:198114. PMC: 7423510. DOI: 10.1016/j.virusres.2020.198114. View

17.

Syed H, Ascoli C, Linssen C, Vagts C, Iden T, Syed A . Infection prevention in sarcoidosis: proposal for vaccination and prophylactic therapy. Sarcoidosis Vasc Diffuse Lung Dis. 2020; 37(2):87-98. PMC: 7569559. DOI: 10.36141/svdld.v37i2.9599. View

18.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View

19.

Kapetanovic M, Kristensen L, Saxne T, Aktas T, Morner A, Geborek P . Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. Arthritis Res Ther. 2014; 16(1):R2. PMC: 3978632. DOI: 10.1186/ar4427. View

20.

Kennedy N, Goodhand J, Bewshea C, Nice R, Chee D, Lin S . Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut. 2021; 70(5):865-875. DOI: 10.1136/gutjnl-2021-324388. View